Michael Finney
Managing Director at Finney Capital
San Francisco, California
Overview
Work Experience
Board Chair
2023 - Current
Member Board of Directors
2007
Interim Chief Executive Officer
2024 - 2024
I've served on the Board of Directors since 2007, became Chair in 2023, and Interim CEO in January 2024. Previously, I served as CEO for over two years, July 2009 to October 2011. Vaxart is a game-changing company with its technology for oral vaccination, and has an excellent team.
CEO
2009 - 2011
Having served on the board since 2007, in 2009 I came in as acting CEO and ended up staying over 2 years. In this time, we closed a $12 million Series B, completed preclinical work, ran a Phase I clinical trial, and hired a permanent CEO.
Vaxart is a biotechnology company that develops vaccine technology for the treatment of infectious diseases.
Raised $138,668,419.00 from RA Capital Management.
Board Chair
2014
Thrive sells instruments and software that automate with extensive imaging, analytics, and AI manual and stem cell culture.
Raised $25,700,000.00 from Xandex Investments LLP.
Director
2019
Enabling single-cell genomics for solid tissues
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.
Raised $18,217,365.00 from BroadOak Capital Partners, Research Corporation Technologies and HealthTech Capital.
Board Chair
2019
Commercializing technology from the Collins lab at UC Berkeley
Managing Director
2004
Director
2016
Reagent systems for DNA sequencing
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services.
Raised $21,394,166.00 from Research Corporation Technologies, BroadOak Capital Partners and Codexis.
Director
1998
Board Chair
2005
Board Chair, December 2015-present
Sage Science is a biotechnology company developing lab instruments and consumables for life sciences research and diagnostic lab markets.
Raised $8,656,388.00 from BPEA.
Director and Permanent Member
1999
Formerly named G Corp, TGP is a non-profit corporation that is responsible for, among other things, the AGBT Genomics meeting. The meeting has been held every February since 2000. It provides an opportunity for academics and commercial companies in the field of genomics to exchange the latest advances.
Advances in Genome Biology and Technology (AGBT) is considered the preeminent genome science and technology conference.
Member
2006
Education
AB
1976 - 1980
Ph.D.
1980 - 1987
Stanford Directors' College
2015 - 2015